Search clinical trials for: first line treatments

Total 23134 results

Massachusetts General Hospital
Medical University of South Carolina; Brown University; Wake Forest University... and other collaborators

Recruiting

Expanding First-line Options for Depression and Matching Treatments to Patients: Hatha Yoga vs. Behavioral Therapy

Depression

United States
Bristol-Myers Squibb

Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) (DISCOVER-HCM)

Obstructive Hypertrophic Cardiomyopathy

United States, Puerto Rico
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Norway, United States, Spain, United Kingdom, Canada
ANRS, Emerging Infectious Diseases
Gilead Sciences

Not yet recruiting

A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide

HIV-1-infection

France
Slovenian Society for Gastroenterology and Hepatology
KRKA

Not yet recruiting

Prospective Randomised Trial of First and Second Line Treatments of RCT of First and Second Line H Pylori Treatments in Slovenia

Helicobacter Pylori Infection | Eradication Treatments

Slovenia
Celgene

Active, not recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Multiple Myeloma

United States, Canada, Italy, Czechia, Denmark, France, Germany, Greece, Spain
Celgene

Active, not recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Spain, United Kingdom
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck Hellas sa., Greece, an affiliate of Merck KGaA, Darmstadt, Germany

Active, not recruiting

Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

Multiple Sclerosis

Greece, Switzerland, Norway, Italy, Poland, Portugal
ANRS, Emerging Infectious Diseases
ViiV Healthcare

Completed

Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone (DOLUVOIR)

HIV-1 Infection

France
SCRI Development Innovations, LLC
Eli Lilly and Company; Genentech, Inc.

Completed

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Lung Cancer

United States
University Hospital, Caen
Genzyme, a Sanofi Company; Ligue contre le cancer, France

Completed

Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration (PREMISEP)

C10.114.375.500

France
Centre Jean Perrin

Terminated

Support and Rehabilitation Protocol for Non Metastatic Breast Cancer Patients in Complete Remission After Chemotherapy

Non Metastatic Breast Cancer

France
St. Franziskus Hospital
Deutsches Institut für Gefäßmedizinische Gesundheitsforschung gGmbH (DIGG); Deutsche Gesellschaft für Gefäßchirurgie und Gefäßmedizin

Completed

Registry of First-line Treatments in Patients With Critical Limb Ischemia (CRITISCH)

Critical Limb Ischemia

Germany
Assistance Publique - Hôpitaux de Paris

Completed

Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus (SAMU-KEPPRA)

Status; Epilepticus, Tonic-clonic

France
Beijing Chest Hospital
The First Affiliated Hospital with Nanjing Medical University; Anhui Chest... and other collaborators

Recruiting

Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis

Tuberculosis | Treatment | Adjuvant

China
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+SOX+Sintilimab as First-line Treatment for Advanced Gastric Cancer

Gastric Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Pancreatic Adenocarcinoma | Advanced Cancer | Drug Use | Capecitabine | Oxaliplatin | First-Line | Cadonilimab | Nanoliposomal Irinotecan

China
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC

Non-small Cell Lung Cancer
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Bristol-Myers Squibb

Not yet recruiting

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

China
Changhai Hospital
Shanghai Chest Hospital; Shanghai Changzheng Hospital; First Affiliated Hospital... and other collaborators

Recruiting

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Non-Small Cell Lung Cancer

China
Guangdong Provincial People's Hospital

Not yet recruiting

PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS

Colorectal Cancer
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
NovoCure GmbH

Recruiting

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain
Bristol-Myers Squibb

Recruiting

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) (RePhlect)

Plaque Psoriasis

Japan
Hospital Universitari de Bellvitge
Hospital Universitario Ramon y Cajal; Complejo Hospitalario de Navarra; University... and other collaborators

Not yet recruiting

EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) (CARPEGIEM)

Biliary Tract Neoplasms | Malignant Biliary Obstruction | Pancreatic Cancer Non-resectable

Spain
AstraZeneca

Not yet recruiting

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC (FOREFRONT)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms

China
Hospital Universitari de Bellvitge
Hospital Universitario Ramon y Cajal; Complejo Hospitalario de Navarra; University... and other collaborators

Not yet recruiting

EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)

Biliary Tract Neoplasms | Pancreatic Cancer Resectable | Malignant Biliary Obstruction

Spain
Hospital Universitari de Bellvitge
Hospital Universitario Ramon y Cajal; Complejo Hospitalario de Navarra; University... and other collaborators

Not yet recruiting

EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial)

Pancreatic Cancer | Biliary Tract Neoplasms | Malignant Biliary Obstruction

Spain
University Hospital, Essen
German Cancer Aid

Not yet recruiting

Exercise in Patients With Advanced Non-small Cell Lung Cancer (BREATH)

Advanced Lung Carcinoma | NSCLC Stage IV | NSCLC Stage IIIB | First Line Treatment | Second Line Treatment | Palliative Treatment | NSCLC Stage IIIC

Germany
Shandong Cancer Hospital and Institute

Recruiting

First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC

Intrahepatic Cholangiocarcinoma

China
Wuhan Union Hospital, China

Recruiting

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Triple-negative Breast Cancer | Cadonilimab

China
The Central Hospital of Lishui City

Not yet recruiting

Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC

Carcinoma | Small Cell Lung Cancer

China
Harbin Medical University
Shanghai Shenqi Medical Technology Co., Ltd

Not yet recruiting

Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial)

Acute Coronary Syndrome (ACS)

China
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of...

Not yet recruiting

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

NSCLC

China
Huihua Xiong

Not yet recruiting

A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

Breast Cancer
Celgene

Not yet recruiting

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Healthy Volunteers

United States
Hutchmed

Not yet recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Daiichi Sankyo
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Extensive Stage-small Cell Lung Cancer
Peking Union Medical College Hospital

Recruiting

Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Biliary Tract Neoplasms Immunotherapy

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
The First Affiliated Hospital of Dalian Medical...

Recruiting

Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC

Long-Term Effects Secondary to Cancer Therapy

China
Bristol-Myers Squibb

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy

Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukaemia

Belgium
Sun Jing

Not yet recruiting

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status

Colorectal Neoplasms | Colorectal Cancer
The First Affiliated Hospital, Guangzhou University...

Not yet recruiting

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Italy, Spain, Poland, Canada, Korea, Republic of, Hungary, Turkey, Taiwan, United Kingdom, Japan, Austria, Australia, Germany, Brazil
Celgene

Not yet recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

United States, Canada, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Japan, Korea, Republic of, Malaysia, Mexico, New Zealand, Norway, Poland, Portug... and more
Qilu Hospital of Shandong University

Not yet recruiting

Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin

Helicobacter Pylori Infection

China
Bristol-Myers Squibb

Not yet recruiting

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Healthy Volunteers | Hepatic Impairment

United States

3

Subscribe